Mylan to Refund Covered Entities for EpiPen Overcharges
Mylan will refund 340B covered entities a total of $19.3 million for overcharges on the EpiPen as part of its recent settlement agreement with the Department of Justice resolving claims…
Fighting to Preserve the Benefits of the 340B Program
Mylan will refund 340B covered entities a total of $19.3 million for overcharges on the EpiPen as part of its recent settlement agreement with the Department of Justice resolving claims…
The Government Accountability Office (GAO) submitted a report on 340B program oversight as part of its testimony during the House Energy and Commerce’s Subcommittee on Oversight and Investigations hearing on…
We received a copy of what we believe to be the Trump Administration’s draft executive order on drug prices that would direct HRSA to scale back the 340B Program. According…
The Senate Health, Education, Labor and Pensions (HELP) Committee will hold a hearing “in the near future” on drug spending. A bipartisan group of senators who serve on the HELP…
A notice from Johnson & Johnson (J&J) was posted on the HRSA website stating that J&J will be issuing refunds to covered entities for overcharges on certain drugs sold between…
The U.S. Government and Accountability Office (GAO) is examining 340B contract pharmacy arrangements, although we do not yet know the purpose of the GAO’s review. The GAO is the investigative…
Several manufacturers of leading antiretroviral drugs increased wholesale acquisition cost (WAC) prices at the beginning of this year, despite an open letter submitted by the Fair Pricing Coalition and more…
Aetna and Humana announced today that they will terminate their merger agreement. Last month, a federal judge blocked the proposed transaction on the grounds that the purchase would violate federal…
Today a federal judge blocked the proposed purchase by Aetna, Inc. of Humana, Inc., holding that the purchase would violate federal antitrust laws. This ruling is good news for 340B…